4.3 Article

Lipid Lowering Agents and the Endothelium: An Update after 4 Years

Journal

CURRENT VASCULAR PHARMACOLOGY
Volume 10, Issue 1, Pages 33-41

Publisher

BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/157016112798829742

Keywords

Endothelial function; statins; ezetimibe; nicotinic acid; fibrates; omega-3 fatty acids

Ask authors/readers for more resources

Endothelial dysfunction represents an important step in the pathogenesis of atherosclerosis. All vascular risk factors can induce endothelial dysfunction, which in turn results in the loss of the protective effects of the endothelium culminating in the development of atherosclerosis. Dyslipidemia is a major vascular risk factor and is associated with endothelial dysfunction. Several studies showed that lipid-lowering agents exert beneficial effects on endothelial function in different populations at increased vascular risk, including patients without dyslipidemia. Therefore, other actions besides lipid-profile modification appear to be implicated in this benefit. However, it is unclear whether the improvement in endothelial function independently contributes to the vascular risk reduction during lipid-lowering treatment (e.g. with statins). It is also unclear whether the assessment of endothelial function would help identify patients who require more aggressive lipid-lowering treatment.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available